SGLT-2 Inhibitors May Reduce Heart Problem Risk
A class of type 2 diabetes drugs known as SGLT-2 inhibitors may reduce the risk for heart problems, a very common complication and cause of death in those with diabetes. Researchers studied the medical charts of more than 300,000 people with type 2 who were taking an SGLT-2 inhibitor or other type 2 medications to manage blood glucose. The international study included all brands of SGLT-2s available in the United States and abroad. Compared with other type 2 meds, treatment with SGLT-2 inhibitors was linked to a 45 percent lower risk of heart failure for people who didn’t have heart disease and a 31 percent lower risk for those who did. Another study, of those with and without heart disease, found something similar: Canagliflozin (Invokana) reduced cardiovascular events by 14 percent for all participants—but there was a drawback. Over the course of a year, the amputation risk was greater for those treated with canagliflozin (6.4 in a thousand) than it was for people who received a placebo (3.4 in a thousand). The reason for the increase in amputation risk with canagliflozin is unknown. It’s possible, however, the risk doesn’t apply to all SGLT-2s: For instance, a previous study of a different SGLT-2 drug, empagliflozin (Jardiance), saw a heart benefit without an increase in amputations.
Source: American Diabetes Association 77th Scientific Sessions